MELD Exceptions for Portopulmonary Hypertension: Current Policy and Future Implementation
Authors:
Open Access
- 1 July 2014
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (9) , 2081-2087
Abstract
No abstract availableKeywords
Funding Information
- NIH (1K08DK098272-01A1)
This publication has 21 references indexed in Scilit:
- Impact of the Hepatopulmonary Syndrome MELD Exception Policy on Outcomes of Patients After Liver Transplantation: An Analysis of the UNOS DatabaseGastroenterology, 2014
- Waitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured ApproachAmerican Journal of Transplantation, 2013
- Underreporting of Liver Transplant Waitlist Removals Due to Death or Clinical DeteriorationTransplantation, 2013
- Pulmonary Vascular Complications of Liver DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Lack of Standardization in Exception Points for Patients With Primary Sclerosing Cholangitis and Bacterial CholangitisAmerican Journal of Transplantation, 2012
- Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertensionLiver Transplantation, 2012
- Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma#*Liver Transplantation, 2012
- Disparities in Liver Transplantation Before and After Introduction of the MELD ScoreJAMA, 2008
- Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment SubgroupsAmerican Journal of Transplantation, 2008
- Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantationLiver Transplantation, 2000